The involvement of the immune system in tumor control is becoming well understood. The tumor environment is in a state of equilibrium between the elimination of cancer cells by the immune system and their proliferation. The immuno-evasion mechanisms that allow tumor cells to remain in equilibrium with the host depends on the overexpression of immunoregulatory molecules such as PD-L1 and its interaction with PD-1 expressed on tumor-infiltrating T lymphocytes. Blocking this interaction is being considered as a more targeted therapeutic approach that blocks the interaction of PD-1 with its ligands, leading to various clinical trial using monoclonal antibodies anti-PD-1 or anti-PD-L1 in several types of cancers. In order to develop such therapies, it is imperative to characterize the interaction between PD-1 and PD-L1. In this webinar we will show how we employed MicroScale Thermophoresis (MST) for the quantitative analysis of the binding affinity between these two molecules. Particularly we describe a method that utilizes low sample consumption and no tedious purification step of the protein of interest.
Most recent content
21:30Fluorescence-Based Technologies for Binding Affinity Studies: Benefits and Labeling Best Practices
Regardless of fluorescence technology (i.e Spectral Shift, TRIC, or FRET), optimizing your labeling strategy is essential to minimize impact on the functionality and ensure accurate Kd measurements
26:58Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
18:36Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi
16:24De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta
Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.
22:59Biologics Formulation: Select optimal buffer conditions with multi-parameter stability characterization from Prometheus Panta
Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving
17:08Assess the impact of bioconjugation with multi-parameter stability characterization
Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.
19:07How stability prediction experiments give you confidence in your ADCs
For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.
20:31The power of Monolith X for Characterizing GPCRs: Accelerating Binding Affinity Measurements
To understand signaling pathways, Spectral Shift technology allows for accurate bindings affinity measurements of membrane proteins like GPCRs in close to native conditions.
14:18Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap
11:48Applying Spectral Shift technology to study IDPs: Direct binding and displacement assays of MYC:MAX inhibitors
MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study
38:20Conversation: How Aaron Frimel from Thermo Fisher Scientific approaches biologics formulation
Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps
19:16How to mitigate risk during ADC development with multi-parameter stability characterization
To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS
38:31nanoDSF for biologics: How to interpret thermal unfolding profiles for your different applications
Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability
24:28Thermal stability measurements for biologics developability profiling
Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.
22:23Selective degradation of cancer target WDR5 — Evaluation of PROTACs binary and ternary affinities with Spectral Shift
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
8:38Explore Prometheus Panta – Frequently asked questions about stability profiling experiments
In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.
20:19Explore Prometheus Panta – Biologics developability assessment with four integrated technologies
Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers. This work entails collecting, ranking, an
16:42How to keep your degrader pipeline moving forward with Dianthus
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
21:31How biologics teams approach developability screening of their candidates with combinatorial stability characterization
Full developability profiles de-risk the selection process for biologics candidates during early development workflows. There are many critical quality attributes to evaluate when it comes to developa
17:33How to use light scattering techniques to predict your biologic's self-association behavior at high concentrations
Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.